mynth
10/2018MajorityLBO

Astorg takes majority stake in Nemera

FRANCE Life Sciences / Medical Devices / Medical Consumables EV €1–10bn

Context

The acquisition of Nemera by Astorg Partners is a strategic move to capitalize on the company's strong market position, predictable revenue streams, and significant growth potential. The deal is driven by the attractiveness of Nemera's business model, which is characterized by long-term contracts, high recurrence rates, and a strong track record of EBITDA growth. Astorg Partners' investment in Nemera is expected to support the company's continued growth and expansion, with a focus on driving innovation, improving operational efficiency, and enhancing customer satisfaction. The transaction is also expected to provide a strong return on investment for Astorg Partners, given Nemera's solid financial performance and growth prospects. The deal process was highly competitive, with several strategic and financial buyers participating in the auction, and Astorg Partners' offer was distinguished by its attractive financial terms and compelling growth strategy.

In the past, Nemera was acquired by Montagu Private Equity in 2014 as part of its expansion strategy.

Nemera, which reported an EBITDA margin of [members only] in 2018, is valued in this transaction at an EV/EBITDA multiple of 15x–25x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Nemera (ex Rexam Healthcare Devices and Prescription Retail) is a leading provider of healthcare devices and pharmaceutical packaging solutions. The company's healthcare devices division designs and manufactures a range of products, including inhalers for asthma, insulin pens, and nasal pumps. The prescription retail division produces flacons and security caps for medications sold in pharmacies. With a strong presence in Europe and the United States, the company has a diverse portfolio of products that cater to various healthcare markets, including pulmonary, parenteral, ENT, dermal, and ophthalmic. The company's products are designed to improve patient outcomes and enhance the overall quality of healthcare. With a rich history and a strong commitment to innovation, Rexam Healthcare Devices and Prescription Retail has established itself as a trusted partner in the healthcare industry.

Ent. Value

€1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

2x–6x

EV / EBITDA

15x–25x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2018
€250–500M
€50–100M
[members only]
2017
€250–500M
€50–100M
[members only]

Other operations with Nemera

Other operations with Nemera
DateAcquirerTargetCountrySector
08/2025LGT CAPITAL PARTNERSNEMERAFRANCEMedical Consumables
02/2014MONTAGU PRIVATE EQUITYNEMERAFRANCEMedical Consumables

Other operations with Astorg

Other operations with Astorg
DateAcquirerTargetCountrySector
03/2021ASTORGXCEPTORUNITED KINGDOMFinancial Services / Banking
06/2020ASTORGNORMECNETHERLANDSTIC (Testing, Inspection, Certification)
04/2020CINVEN / ASTORGLGC GROUPUNITED KINGDOMTIC (Testing, Inspection, Certification)
02/2019ASTORGANAQUAUNITED STATESIndustry-Specific Software
04/2016ASTORGFLOWBIRD (EX PARKEON)FRANCEIndustry-Specific Software
02/2016ASTORG / GOLDMAN SACHSHRA PHARMAFRANCEGenerics / Labs
04/2015ASTORGMETROLOGIC GROUPFRANCESupply Chain & Ops
12/2013ASTORGKERNEOSFRANCEConstruction Materials
11/2007ASTORGTRESCALFRANCETIC (Testing, Inspection, Certification)
04/2007ASTORGETHYPHARMFRANCEPharma & Biotech

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
12/2018MERCK & CO.ANTELLIQFRANCEAnimal Health
11/2018ARDIANNEOPHARMED GENTILIITALYGenerics / Labs
10/2018ARDIANINULA GROUPBELGIUMPharma & Biotech
10/2018GLANBIASLIMFASTUNITED STATESNutrition & Dietary Supplements
10/2018BRIDGEPOINTHTL BIOTECHNOLOGYFRANCECDMO
08/2018DENTRESSANGLEACTEONFRANCEMedical Devices
05/2018NNPARAGON MEDICALUNITED STATESMedical Devices
05/2018ZOETISABAXISUNITED STATESDiagnostic Equipment
05/2018PERMIRACORIN GROUPUNITED KINGDOMImplants & Prosthetics
12/2017PERKINELMEREUROIMMUN MEDICAL LABORATORY DIAGNOSTICSGERMANYDiagnostic Equipment

REFERENCES

Valuation range: EV €1–10bn

Revenue range: €250–500M

EBITDA range: €50–100M

EV/Revenue range: 2x - 6x

EV/EBITDA range: 15x - 25x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Nemera by Astorg are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: nemera

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Nemera, a French company specialised in Medical Devices, by Astorg in 2018, structured as a leveraged buyout (LBO). This followed a prior holding cycle initiated by Montagu Private Equity in February 2014, before ownership was subsequently transferred to LGT Capital Partners in August 2025 (see dedicated deal pages for details).

How was the acquisition of Nemera by Astorg valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €1–10bn band, its EV/EBITDA multiple within the 15x - 25x range, and its EV/revenue multiple within the 2x - 6x range. Exact figures are available to members.

What were Nemera’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Nemera generated annual revenue estimated in the €250–500M range and EBITDA in the €50–100M bracket (FY 2018). Detailed financial figures are available to members.

What sources support the information on this transaction?

Data on this transaction was compiled from the official corporate announcement published by the parties, combined with independent reporting from specialized financial and M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.